VIAL

Medical Weight Loss & Management

48 verified Weight Loss providers in Vial’s directory.

What is Weight Loss?

The compounded GLP-1 market moved faster than its regulatory infrastructure. Semaglutide and tirzepatide became household names before most patients understood the difference between the FDA-approved products and compounded alternatives, or how to evaluate the pharmacies producing them. As retatrutide and next-generation compounds enter the pipeline, the landscape will keep evolving. What stays constant is the need to verify who is prescribing, who is compounding, and whether operational standards match marketing claims. Vial maps weight loss providers against FDA enforcement history, PCAB accreditation, DEA registration, and physician oversight structure.

Top Weight Loss providers in Vial’s directory

Ranked by Trust Score. Showing 10 of 48. See all Weight Loss providers →

How Vial evaluates Weight Loss providers

Vial verifies medical weight loss providers across six dimensions: regulatory standing, clinical transparency, pharmacy and fulfillment, commercial transparency, operating history, and industry standing. For weight loss specifically, we surface pricing transparency and pharmacy disclosure prominently — the gap between branded and compounded GLP-1 access depends entirely on which pharmacy fulfills your prescription.

Read the full methodology →

Weight Loss compounds

Compounds commonly used in Weight Loss protocols. See all compounds →

Weight LossFDA Approved
Semaglutide
A synthetic glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide mimics the incretin hormone GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. The compound also acts on hypothalamic receptors to reduce appetite and food intake. Primary clinical applications include the management of type 2 diabetes mellitus and chronic weight management in individuals with obesity or overweight with weight-related comorbidities.
Legal Compounded→
Weight LossFDA Approved
Tirzepatide
A synthetic dual agonist peptide, tirzepatide activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. The compound produces significant improvements in glycemic control and body weight reduction. Primary clinical applications include treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity.
Legal Compounded→
MetabolicClinical Trials
Retatrutide
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, representing the most mechanistically advanced anti-obesity peptide in late-stage clinical development. Phase II trials reported mean body weight reductions of 24% over 48 weeks — the largest pharmacological weight loss ever recorded in a randomized controlled trial. It is being developed by Eli Lilly and is expected to enter Phase III trials in 2025–2026.
Grey Area→
MetabolicClinical Trials
Liraglutide
Liraglutide is a once-daily GLP-1 receptor agonist marketed as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first GLP-1 agents to demonstrate meaningful weight loss in clinical trials, producing 5–8% body weight reduction on average. Though largely superseded by weekly agents, it remains a clinically validated option. Compounded liraglutide is available through select pharmacies.
FDA Approved→

Frequently Asked Questions

Related pillars

Longevity (overview)